

Dequalinium Chloride - A Breakthrough Treatment of Vaginitis



Relief from **vaginitis** redefined

Drug Review

About Vaginitis

- Vaginitis is a condition with symptoms of abnormal vaginal discharge, odor, irritation, itching, or burning impacting quality of life.
- The most common causes of vaginitis are bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis and mixed infections.
- Bacterial vaginosis is implicated in 40% to 50%, vulvovaginal candidiasis in 20% to 25% & trichomoniasis for 15% to 20% of identified vaginitis cases.¹
- Usual treatments show similar acceptable short-term efficacy, but frequent recurrences and increasing microbial resistance are unsolved issues.
- Vaginal infections are associated with a variety of serious adverse outcomes in pregnancy.
- Identifying the correct therapy can be challenging for the clinician, particularly in mixed infections and it needs broad spectrum anti- infective preparation.²

Dequalinium Chloride (DQC) - Non Systemic, Non Antibiotic, Broad Spectrum Anti-Infective²

- DQC is an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity.
- The primary mechanism of action increases bacterial cell permeability and the subsequent loss of enzyme activity.
- However, it has unique triple mode of action against bacteria




Fig: Triple mode of action

Dequalinium chloride is an anti-infective, antiseptic agent with a broad bactericidal & fungicidal activity and effective & safe empirical treatment in the management of vaginitis.²

Proven Results

- DQC has a broad antimicrobial activity against Gram-Positive, Gram-Negative bacteria, candida, protozoa.²
- The bactericidal and fungicidal effect of DQC has been demonstrated to occur within 30–60 min.³
- Resistance of pathogens is unlikely due to the multiple mode of action of DQC.⁴
- DQC is absorbed only to a very small amount after vaginal application. Hence there is no chance of systemic adverse effects.⁵
- DQC as 6-day therapy offers a safe and effective option for empiric therapy of different vaginal infections in daily practice.²
- The tolerability and safety of the treatment was excellent and no ADRs were reported on pregnant women and new-born.²



Optimum Efficacy at Low MIC₉₀²

Group	Pathogen	MIC ₉₀ (μ g/ml)
GramPositive Bacteria	Group B streptococci	2-64
	Staphylococcus aureus	0.2-8
GramNegative Bacteria	Gardnerella vaginalis	2-256
	Echerichia coli	1-400
Fungi	Klebsiella spp	3.1-400
	Candida albicans	0.2-50
	Candida glabrata	0.2-256
Protozoa	Candida tropicalis	0.2-50
	Trichomonas vaginalis	28.8-400

- Dequalinium chloride concentration in the vaginal fluid is 2000-4000 μ g/ml.
- This concentration in vaginal fluid is minimum 4 to 8 times higher than the required MIC90 of causative pathogens causing Vaginitis.

For the **first time in Bangladesh**, breaking the barrier in multiple forms of **Vaginitis** with one simple therapy



Relief from vaginitis redefined

Dekalin VT (Dequalinium Chloride) is highly effective in multiple forms of Vaginitis²



96%
in Bacterial
Vaginosis



77.80%
in Non specific
Vaginitis



76%
Fungal
Infection



60%
Trichomonal
Infection

Once Daily for **6** Days at Night



Dekalin VT is now with



Easy to Administer

Applicator
and user guideline

Reference: 1. Am Fam Physician. 2018 Mar 1;97(5):321-329.; 2. Arch Gynecol Obstet (2016) 293:469-484.; 3. Ann Ig 1:1227-1241.; 4. Antimicrob Agents Chemother 41(2):440-444.; 5. J Pharm Pharmacol 8:110-119



Nuvista Pharma PLC. (a subsidiary of Beximco Pharma)
Dhaka-1216, Bangladesh | www.nuvistapharma.com | [nuvistapharma](#)

DEK-DRV010126PYM